Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Overview of attention for article published in Journal of Clinical Oncology, July 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 9 news outlets
policy: 1 policy source
twitter: 10 X users
patent: 4 patents

facebook: 3 Facebook pages
wikipedia: 2 Wikipedia pages
guideline: 4 clinical guideline sources

Readers on

mendeley: 422 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 12 news stories from 9 outlets.

Prosigna Breast Cancer Assay Outperforms All Other Commercial Assays Tested in Updated Analysis of TransATAC Study Presented at the 39th Annual CTRC-AACR San Antonio Breast Cancer Symposium

Biz Wire Express, 12 Dec 2016

GlobeNewswire 2016-12-12 SM. For post-menopausal women with node-negative, hormone receptor-positive, HER2-negative early stage…

Prosigna Breast Cancer Assay Outperforms All Other Commercial Assays Tested in Updated Analysis of TransATAC Study Presented at the 39th Annual CTRC-AACR San Antonio Breast Cancer Symposium

Benzinga, 12 Dec 2016

Prosigna Provides the Most Prognostic Information of Four Genomic Tests in Head-to-Head Comparison of Early Breast Cancer Node-Ne…

Prosigna Breast Cancer Assay Outperforms All Other Commercial Assays Tested in Updated Analysis of TransATAC Study Presented at the 39th Annual CTRC-AACR San Antonio Breast Cancer Symposium

Yahoo! Finance USA, 12 Dec 2016

Prosigna Provides the Most Prognostic Information of Four Genomic Tests in Head-to-Head Comparison of Early Breast Cancer Node-Ne…

Prosigna Breast Cancer Assay Outperforms All Other Commercial Assays Tested in Updated Analysis of TransATAC Study Presented at the 39th Annual CTRC-AACR San Antonio Breast Cancer Symposium

NASDAQ, 12 Dec 2016

Prosigna Provides the Most Prognostic Information of Four Genomic Tests in Head-to-Head Comparison of Early Breast Cancer Node-Ne…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 8 additional news stories.